The anti-dyskinetic effect of the clinically-available 5-HT3 receptor antagonist granisetron in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of the serotonin 3 (5-HT3) receptor antagonist granisetron, a clinically-available anti-emetic, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Dopamine replacement with L-DOPA…Does motor laterality affect the development of dyskinesia in patients with Parkinson’s disease?
Objective: To investigate the effects of motor laterality on the development of levodopa-induced dyskinesia (LID) in patients with de novo Parkinson’s disease (PD). Background: LID…Dysphagia predicts poor outcome in late-stage Parkinson’s disease
Objective: to evaluate the clinical progression and prognostic factors of a late-stage PD (LSPD) population. Background: Parkinson’s disease (PD) disability milestones emerge in an exponential…Personal KinetiGraph™ Movement Recording System: An Assessment of Utility in a Movement Disorder Clinic
Objective: The objective of this open-label study was to evaluate the clinical utility of the Personal KinetiGraph™ (PKG) Movement Recording System in the care of…Levodopa effect on non-motor symptoms in late stage Parkinson’s disease
Objective: To assess responsiveness of non-motor symptoms (NMS) to Levodopa (L-dopa) and to describe the NMS burden in late stage Parkinson's disease (PD). Moreover, to…Gastric Retention of the Accordion Pill™: Results From MRI Studies With Parkinson’s Disease Patients and Healthy Volunteers
Objective: To determine gastric retention (GR) of the Accordion Pill™ (AP) in patients with Parkinson’s disease (PD) and healthy volunteers. Background: While carbidopa/levodopa (CD/LD) is…L-Dopa responsiveness in early Parkinson’s disease: Results from the United Kingdom Tracking Parkinson’s study
Objective: We wanted to evaluate L-dopa responsiveness in a large cohort of patients with recently diagnosed Parkinson’s disease (PD) using an acute L-dopa challenge test.…High dose of levodopa and Segawa disease
Objective: To analyze the dose-dependent effects of levodopa on the symptoms of the disease in our case. Background: In 1976, Segawa et al. reported dopa-responsive…Effects of L-DOPA on Quantitative Gait Parameters Measured with Wearable Sensors
Objective: To quantify and validate the ability of wearable sensors to detect response to symptomatic medication in Parkinson's Disease (PD). Background: While clinical visual assessment…Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease
Objective: To genetically abrogate Fyn expression to reduce levodopa induced dyskinesia (LID) in the 6-OHDA mice model of Parkinson’s disease (PD), using intrastriatal-injected lentiviral (LV)…
- « Previous Page
- 1
- …
- 44
- 45
- 46
- 47
- 48
- …
- 62
- Next Page »